Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06617845 · ClinicalTrials.gov registry record · NA

Optimizing Brain Stimulation Parameters

A NA study of Epilepsy; Seizure, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06617845: Recruiting NA study of Epilepsy; Seizure, sponsored by Mayo Clinic.

NCT06617845 is a NA study of Epilepsy; Seizure that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 779-participant average among 4 other Epilepsy; Seizure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06617845, a NA study of Epilepsy; Seizure, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

A primary purpose of this study is to better understand what stimulation parameters work best for patients. For example, for Deep Brain Stimulation (DBS) of the Anterior Nucleus of the Thalamus (ANT), it is not clear what stimulation frequency leads is most effective. This study will help assess the effectiveness of low frequency or high frequency stimulation.

Primary Outcome

Using the Mayo Epilepsy Short Assessment as well as patient diaries, seizure frequency is determined.

Conditions Studied

Interventions

  • DEVICE Stimulation Set A and B

Study Locations (1)

Minnesota

  • Mayo Clinic Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-10-20
Est. Completion 2028-09-01
Phase NA
Mayo Clinic

2,844 total trials

What NCT06617845 shows while recruiting

NCT06617845 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 779-participant average among 4 other Epilepsy; Seizure trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Epilepsy; Seizure appearing as the primary indexed condition, and to 1 intervention - of which Stimulation Set A and B is the first listed.

NCT06617845 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06617845 about?

NCT06617845 is a clinical study titled "Optimizing Brain Stimulation Parameters". A primary purpose of this study is to better understand what stimulation parameters work best for patients. For example, for Deep Brain Stimulation (DBS) of the Anterior Nucleus of the Thalamus (ANT), it is not clear what stimulation frequency leads is most effective. This study will help assess the...

What is the current status of trial NCT06617845?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-10-20. Estimated completion is 2028-09-01.

What conditions does trial NCT06617845 study?

This clinical trial studies the following conditions: Epilepsy; Seizure.

What interventions are being tested in trial NCT06617845?

The interventions under investigation include: Stimulation Set A and B (DEVICE).

Who is sponsoring clinical trial NCT06617845?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06617845 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy; Seizure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06617845, the US trial registry maintained by the National Library of Medicine. NCT06617845 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.